Cabozantinib in Kidney Cancer: Longest PFS YetCabozantinib in Kidney Cancer: Longest PFS Yet
Another presentation hailed as practice changing for renal cell carcinoma shows the longest progression-free survival yet in pretreated patients. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hematology | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology